Monte Rosa Therapeutics (GLUE) Common Equity (2020 - 2026)

Monte Rosa Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $521.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 89.68% year-over-year to $521.9 million; the TTM figure through Mar 2026 stood at $521.9 million (up 89.68% YoY), while the FY2025 annual figure was $233.1 million, up 4.54% from the prior year.
• Common Equity was $521.9 million for Q1 2026 at Monte Rosa Therapeutics, up from $233.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $521.9 million in Q1 2026 to a low of $152.5 million in Q1 2024.
• Historically, Common Equity has averaged $256.5 million across 5 years, with a median of $243.7 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 637.61% in 2022, then slumped 37.42% in 2024.
• A 5-year view of Common Equity shows it stood at $271.4 million in 2022, then slumped by 33.96% to $179.2 million in 2023, then gained by 24.37% to $222.9 million in 2024, then increased by 4.54% to $233.1 million in 2025, then surged by 123.94% to $521.9 million in 2026.
• The last three Common Equity figures came in at $521.9 million (Q1 2026), $233.1 million (Q4 2025), and $245.8 million (Q3 2025), per Business Quant data.